WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has signed an asset purchase agreement with Nephromics LLC, which includes a patent license for exclusive rights to use PlGF (Placental Growth Factor) for the diagnosis of pre-eclampsia or eclampsia. Clinical trials have shown that PlGF supports the diagnosis and risk prediction for preeclampsia (PE). Thermo Fisher will develop PlGF as an immunoassay on its own KRYPTOR™ platform and, through management of several sublicenses under the acquired license, will strengthen its global position in prenatal screening by expanding the availability of the assay through license partners.
